MONTPELLIER, FRANCE — Sensorion has received authorization from France’s National Agency for Medicines and Health Products Safety (ANSM) to begin a Phase I/II clinical trial of SENS-601, its investigational gene therapy targeting GJB2-related hearing loss. The authorization, granted August 31 through ANSM’s Fast Track assessment process, clears the company to initiate the HearConnex clinical trial in France....
Continue reading at Hearing Health Matters
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a Phase I/II trial authorization; no safety or efficacy data are yet available for clinical consideration.
GJB2-related hearing loss is the most common form of inherited deafness, so a gene therapy entering human trials marks a significant milestone that could eventually reshape early intervention options for this population.
- 01Sensorion received ANSM (French regulatory authority) authorization to begin a Phase I/II trial of SENS-601.
- 02SENS-601 targets GJB2-related hereditary hearing loss, the most prevalent genetic cause of congenital deafness.
- 03This is a first-in-human safety and preliminary efficacy trial; no results are yet available.
- 04The announcement is a regulatory milestone, not a product approval or clinical outcome report.
- 05Gene therapy for GJB2 hearing loss remains investigational with an unknown timeline to market.
Sensorion has received ANSM authorization to begin a Phase I/II clinical trial of SENS-601 for GJB2-related hereditary hearing loss.
press releasesupportedSENS-601 is an investigational gene therapy targeting GJB2-related hereditary hearing loss.
press releaseunclear
